title: Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions.
abstract: Kawasaki disease (KD) is a syndrome of systemic vasculitis of unknown etiology that is complicated by coronary artery lesions (CAL), leading occasionally to cardiac ischemic sequelae. To examine whether vascular endothelial growth factor (VEGF) is responsible for CAL in KD, we determined serum VEGF levels by ELISA and peripheral blood mononuclear cell (PBMC) and neutrophil VEGF expression by immunoblot analysis. Significantly increased levels of VEGF were demonstrated in acute KD as well as in other vasculitis syndromes (p < 0.0001). In the 10 KD patients with CAL, serum VEGF levels were maximal approximately 2 wk post-onset when CAL generally develops and were significantly higher than in 20 patients without CAL (mean, 474 and 241 pg/mL, respectively; p = 0.00015). During the same period, immunoblot analysis revealed maximal VEGF expression in PBMC, corresponding to serum VEGF levels in most patients and being particularly marked in patients with CAL (p < 0.01). Neutrophils expressed VEGF only in the early stage of acute KD and declined rapidly in the majority of KD patients regardless of the presence of CAL, showing a strikingly different expression pattern than that for PBMC. Predominant VEGF expression by PBMC was also demonstrated in patients with other vasculitis syndromes and only faintly in normal controls. The results suggest that VEGF is generated dynamically in KD, presumably reflecting its disease activity. Neutrophil-derived VEGF may play a role in regulating early vascular responses, whereas PBMC-derived VEGF may contribute to later vascular injury and remodeling.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hamamichi
authors.forename: F
authors.initials: F
authors.lastname: Ichida
authors.forename: X
authors.initials: X
authors.lastname: Yu
authors.forename: K I
authors.initials: KI
authors.lastname: Hirono
authors.forename: K I
authors.initials: KI
authors.lastname: Uese
authors.forename: I
authors.initials: I
authors.lastname: Hashimoto
authors.forename: S
authors.initials: S
authors.lastname: Tsubata
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: T
authors.initials: T
authors.lastname: Futatani
authors.forename: H
authors.initials: H
authors.lastname: Kanegane
authors.forename: T
authors.initials: T
authors.lastname: Miyawaki
mesh_terms: D000293:Adolescent; D015153:Blotting, Western; D002648:Child; D002675:Child, Preschool; D003327:Coronary Disease / Q000097:blood* / Q000473:pathology; D018450:Disease Progression; D016228:Endothelial Growth Factors / Q000097:blood / Q000502:physiology*; D005434:Flow Cytometry; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008222:Lymphokines / Q000097:blood / Q000502:physiology*; D009000:Monocytes / Q000378:metabolism*; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood* / Q000473:pathology; D009504:Neutrophils / Q000378:metabolism*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors